Thus weight loss, whether mediated by GLP-1 agonists or other means, may be effective in improving symptoms in individuals with obesity and knee OA, but may not change the progression of knee and hip OA in the same population. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.